Loading

Review Article Open Access
Volume 1 | Issue 3 | DOI: https://doi.org/10.33696/Signaling.1.013

Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS

  • 1Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA
  • 2Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, Florida, USA
  • 3Department of Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA
+ Affiliations - Affiliations

Corresponding Author

Alla Mitrofanova, a.mitrofanova@miami.edu

Received Date: July 01, 2020

Accepted Date: July 20, 2020

Abstract

Sphingolipids are well-recognized as major players in the pathogenesis of many human diseases, including chronic kidney disease. The kidney is a very sensitive organ to alterations in sphingolipid metabolism. The critical issues to be addressed in this review relate to the role of sphingolipids and enzymes involved in sphingolipid metabolism in the pathogenesis of glomerular diseases with a special focus on podocytes, a key cellular component of the glomerular filtration barrier. Among several sphingolipids, we will highlight the role of ceramide, sphingosine, sphingosine-1-phosphate and ceramide-1-phosphate. Additionally, we will summarize the current knowledge with regard to the use of sphingolipids as therapeutic agents for the treatment of podocyte injury in kidney disease.

Keywords

Kidney, DKD, FSGS, Podocyte, Sphingolipids, SMPDL3b, S1P, C1P, Ceramide

Author Information X